ArcticZymes Technologies ASA (OSL:AZT)
Norway · Delayed Price · Currency is NOK 19.65
+0.15 (0.77%)
Apr 1, 2026, 1:05 PM CET
OSL:AZT Revenue
In the year 2025, ArcticZymes Technologies ASA had annual revenue of 118.21M NOK with 9.34% growth. ArcticZymes Technologies ASA had revenue of 34.66M in the quarter ending December 31, 2025, with 31.10% growth.
Revenue
118.21M
Revenue Growth
+9.34%
P/S Ratio
8.49
Revenue / Employee
2.23M
Employees
53
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.21M | 10.10M | 9.34% |
| Dec 31, 2024 | 108.11M | -11.54M | -9.65% |
| Dec 31, 2023 | 119.65M | -18.02M | -13.09% |
| Dec 31, 2022 | 137.67M | 6.62M | 5.05% |
| Dec 31, 2021 | 131.05M | 33.23M | 33.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aqua Bio Technology ASA | 101.51M |
| Arctic Bioscience AS | 45.90M |
| Oncoinvent ASA | 20.00M |
| SoftOx Solutions AS | 15.58M |
| PCI Biotech Holding ASA | 4.69M |
| Nykode Therapeutics AS | 4.57M |
| Thor Medical ASA | 839.00K |
| Lytix Biopharma AS | 377.00K |